Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products

  Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards
                                Their Products

PR Newswire

LONDON, January 30, 2013

LONDON, January 30, 2013 /PRNewswire/ --

EmergingGrowth.com, a leading digital financial media company, discusses
Sunesis Pharmaceuticals, Amgen, Inc., Gilead Sciences and Biogen Idec, Inc.

The pharmaceuticalsector is a very lucrative and competitive industry. And
for emerging growth companies, it is difficult to make a meaningful impact in
this cutthroat industry.

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) has built a highly experienced
cancer drug development organization committed to advancing its lead product
candidate, Vosaroxin, to improve the lives of people with cancer.

Sunesis Pharmaceuticals' work translates to a rosy top line as demonstrated by
the $25 million it earned from a previously announced royalty purchase
agreement with Royalty Pharma. It took possession of $15 million from the
second tranche of a 2011 venture loan facility. It raised $17.3 million from
the sale of 3.6 million shares of common stock and $1.4 million from the gross
exercise of 0.6 million warrants to purchase common stock. This not only shows
that Sunesis is able to raise capital for research purposes, but it also
represents the company's keen interest in creating shareholder value.

The company isin the follow-up stage of trials of Vosaroxin, havingcompleted
a Phase 2 trial in ovarian cancer patients in 2010. However, broader market
tailwinds will propel the company through the next decade. Vosaroxin is a
first-in-class anticancer quinolone derivative, a class of compounds that has
not been used previously for the treatment of cancer. As of now, notable
breakthroughs are being made with the drug, particularly as complete
remissions have been observed in patients treated with Vosaroxin in
combination with Cytarabine.

Just like its bigger competitors, Amgen Inc. (NASDAQ: AMGN) andGilead
Sciences Inc. (NASDAQ: GILD), Sunesis also wants to make a big impact. To
ensure this, it has entered into a collaboration agreement with Millennium
Pharmaceuticals for the development of Sunesis' inhibitor. It alsoannounced
the license of the company's LFA-1 inhibitor program to SARcode Corporation, a
privately held bio-pharmaceutical company. In addition,it has announced a
collaboration agreement with Biogen Idec Inc. (NASDAQ: BIIB) to discover,
develop, and commercialize inhibitors of Raf kinase and up to five additional
oncology kinase targets.

All these developments will signal the market's gravitation toward Sunesis
products. Considering that ovarian cancer is the eighth most common cancer
among women, it would be accurate to say that vosaroxin will be relevant in
the market. In addition, the future promise of FDA approval brightens the
long-term picture and promises longevity. With a market capitalization of $226
million and a 52-week range $1.29 - $6.85 (the stock is currently trading
close to its high at around $4), it would be accurate to say that Sunesis
Pharmaceuticals will gain tremendous value in the next few years.

NEW: Feature your company on EmergingGrowth.com. Find out how by filling out
our referral form here:

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial
reporters, writers and bloggers in the business, EmergingGrowth.com is
emerging as a leading digital financial media portal. Its services provide
users, subscribers and advertisers with a variety of content and tools through
a range of online, social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other
financial media companies with its sly approach to reading between the lines
in order to locate that needle in the haystack. Sign up today to see what
EmergingGrowth.com has to offer.

Join our LinkedIn Group…

Like us on Facebook...


All information contained herein as well as on the EmergingGrowth.com website
is obtained from sources believed to be reliable but not guaranteed to be
accurate or all-inclusive. All material is for informational purposes only, is
only the opinion of EmergingGrowth.com and should not be construed as an offer
or solicitation to buy or sell securities. In addition, Please make sure you
read and understand the Terms of Use, Privacy Policy and the Disclosure posted
on the EmergingGrowth.com website. Always remember that investing in
securities such as the ones listed within are for high-risk tolerant
individuals only and not the general public. Whether you are an experienced
investor or not, you should always consult with a stockbroker, financial
advisor, or similar before purchasing or selling any securities viewed on any
emails sent from EmergingGrowth.com or its website.

SOURCE EmergingGrowth.com

Contact: Contact: EmergingGrowth.com, info@EmergingGrowth.com, +1-305-323-5687
Press spacebar to pause and continue. Press esc to stop.